keyword
MENU ▼
Read by QxMD icon Read
search

deferasirox

keyword
https://www.readbyqxmd.com/read/27928480/a-review-on-iron-chelators-in-treatment-of-iron-overload-syndromes
#1
REVIEW
Naser Mobarra, Mehrnoosh Shanaki, Hassan Ehteram, Hajar Nasiri, Mehdi Sahmani, Mohsen Saeidi, Mehdi Goudarzi, Hoda Pourkarim, Mehdi Azad
Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality...
October 1, 2016: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/27893351/management-of-iron-overload-in-myelodysplastic-syndromes-combined-deferasirox-and-deferoxamine-in-a-patient-with-liver-disease
#2
Claudio Cerchione, Giuseppe Cerciello, Simona Avilia, Roberta Della Pepa, Novella Pugliese, Marco Picardi, Lucio Catalano, Fabrizio Pane
No abstract text is available yet for this article.
October 24, 2016: Blood Transfusion, Trasfusione del Sangue
https://www.readbyqxmd.com/read/27893170/safety-profiles-of-iron-chelators-in-young-patients-with-haemoglobinopathies
#3
REVIEW
Sebastian Botzenhardt, Niya Li, Esther W Chan, Chor Wing Sing, Ian C K Wong, Antje Neubert
BACKGROUND: This review describes the safety of deferoxamine (DFO), deferiprone (DFP), deferasirox (DFX), and combined therapy in young patients less than 25 years of age with haemoglobinopathies. METHOD: Searches in electronic literature databases were performed. Studies reporting adverse events associated with iron chelation therapy were included. Study and reporting quality was assessed using AHRQ Risk of Bias Assessment Tool and McMaster Quality Assessment Scale of Harms...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27881236/deferasirox-pharmacokinetics-evaluation-in-a-woman-with-hereditary-haemochromatosis-and-heterozygous-%C3%AE-thalassaemia
#4
Sarah Allegra, Silvia De Francia, Filomena Longo, Davide Massano, Jessica Cusato, Arianna Arduino, Elisa Pirro, Antonio Piga, Antonio D'Avolio
We present the deferasirox pharmacokinetics evaluation of a female patient on iron chelation, for the interesting findings from her genetic background (hereditary haemochromatosis and heterozygous β-thalassaemia) and clinical history (ileostomy; iron overload from transfusions). Drug plasma concentrations were measured by an HPLC-UV validated method, before and after ileum resection. Area under deferasirox concentration curve over 24h (AUC) values were determined by the mixed log-linear rule, using Kinetica software...
November 20, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27879229/the-incidence-of-ototoxicity-in-patients-using-iron-chelators
#5
Serhan Derin, Fatih Mehmet Azık, Yaşar Topal, Hatice Topal, Volkan Karakuş, Petek Uzay Çetinkaya, Murat Şahan, Tansel Erdem Azık, Can Naci Kocabaş
OBJECTIVE: In this study, we aimed to detect the incidences of ototoxicity in patients with hemoglobinopathies taking deferoxamine (DFO), deferiprone, and deferasirox using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) scale to obtain more objective data. MATERIALS AND METHODS: Fifty-five transfusion-dependent patients were evaluated in this study. The NCI CTCAE scale was used to assess ototoxicity levels. The average ferritin and hemoglobin levels, the type of iron chelator, and the duration of therapy of all the patients were recorded...
November 23, 2016: Journal of International Advanced Otology
https://www.readbyqxmd.com/read/27859648/limitations-of-serum-ferritin-to-predict-liver-iron-concentration-responses-to-deferasirox-therapy-in-patients-with-transfusion-dependent-thalassemia
#6
John B Porter, Mohsen Elalfy, Ali Taher, Yesim Aydinok, Szu-Hee Lee, Pranee Sutcharitchan, Ali El-Ali, Jackie Han, Amal El-Beshlawy
BACKGROUND: In transfusion-dependent anaemias, while absolute serum ferritin levels broadly correlate with liver iron concentration (LIC), relationships between trends in these variables are unclear. These relationships are important because serum ferritin changes are often used to adjust or switch chelation regimens when liver magnetic resonance imaging (MRI) is unavailable. OBJECTIVES AND METHODS: This post-hoc analysis of the EPIC study compared serum ferritin and LIC in 317 patients with transfusion-dependent thalassaemia before and after 1 year of deferasirox...
November 17, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27833388/effects-of-an-oral-iron-chelator-deferasirox-on-advanced-hepatocellular-carcinoma
#7
Issei Saeki, Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Masaki Maeda, Koichi Fujisawa, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Koichi Uchida, Kenji Tani, Isao Sakaida
AIM: To evaluate the inhibitory effects of deferasirox (DFX) against hepatocellular carcinoma (HCC) through basic and clinical studies. METHODS: In the basic study, the effect of DFX was investigated in three hepatoma cell lines (HepG2, Hep3B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day...
October 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27809710/the-questioning-for-routine-monthly-monitoring-of-proteinuria-in-patients-with-%C3%AE-thalassemia-on-deferasirox-chelation
#8
Turan Bayhan, Şule Ünal, Ozan Ünlü, Hakan Küçüker, Anıl Doğukan Tutal, Erdem Karabulut, Fatma Gümrük
BACKGROUND: Iron chelation therapy is one of the mainstays of the management of the patients with β-thalassemia (BT) major. Deferasirox is an oral active iron chelating agent. Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency. METHODS: We aimed to investigate the necessity for monthly monitoring for proteinuria among patients with BT on deferasirox...
November 3, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27771776/multidisciplinary-evaluation-at-baseline-and-during-treatment-improves-the-rate-of-compliance-and-efficacy-of-deferasirox-in-elderly-myelodysplastic-patients
#9
Lisette Del Corso, Lucia Biale, Emanuele Luigi Parodi, Rodolfo Russo, Rosa Filiberti, Eleonora Arboscello
BACKGROUND: Deferasirox (DFX) is used to reduce iron levels in patients with myelodysplastic syndrome (MDS) who develop iron overload after chronic red blood cell infusions. However, DFX can be associated with renal and gastrointestinal toxicities, which may cause treatment interruption or discontinuation. This study aimed to determine the effectiveness and safety of DFX in patients with MDS. METHODS: This multicenter, retrospective, observational study was conducted at two hospitals in Italy...
October 22, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27697722/determination-of-deferasirox-in-human-plasma-by-short-end-injection-and-sweeping-with-a-field-amplified-sample-stacking-and-micellar-electrokinetic-chromatography
#10
Hung-Ju Lin, Kun-Pin Hsieh, Shyh-Shin Chiou, Hwang-Shang Kou, Shou-Mei Wu
A field-amplified sample stacking-sweeping micellar electrokinetic chromatography with short-end injection was established for determination of deferasirox (DFX) in plasma. DFX was extracted from plasma and reconstituted with deionized water (lower conductivity solution). Capillary (effective length, 10cm) was filled with background electrolyte (40mM phosphate buffer, pH 4.5, containing 20% methanol). After sample loading from outlet end at 5psi for 15s, separation was carried out by applying high voltage at 15kV for 10min...
November 30, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27672004/deferasirox-pharmacokinetic-and-toxicity-correlation-in-%C3%AE-thalassaemia-major-treatment
#11
Sarah Allegra, Silvia De Francia, Jessica Cusato, Elisa Pirro, Davide Massano, Antonio Piga, Antonio D'Avolio
OBJECTIVES: Deferasirox adverse effects include the following: gastrointestinal disturbance, mild elevations in serum creatinine levels and intermittent proteinuria; these events are dose-dependent and reversible with drug discontinuation, but this solution can lead to an inadequate iron chelation. For these reasons, interindividual variability of drug plasma concentration could help the clinical management of deferasirox dosage. We sought to describe deferasirox plasma exposure in a cohort of 60 adult patients...
September 27, 2016: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/27621572/supportive-therapies-for-prevention-of-hepatocellular-carcinoma-recurrence-and-preservation-of-liver-function
#12
REVIEW
Taro Takami, Takahiro Yamasaki, Issei Saeki, Toshihiko Matsumoto, Yutaka Suehiro, Isao Sakaida
Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world and is associated with a high risk of recurrence. The development of a wide range of new therapies is therefore essential. In this study, from the perspective of supportive therapy for the prevention of HCC recurrence and preservation of liver function in HCC patients, we surveyed a variety of different therapeutic agents. We show that branched chain amino acids (BCAA) supplementation and late evening snack with BCAA, strategies that address issues of protein-energy malnutrition, are important for liver cirrhotic patients with HCC...
August 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27606437/health-related-quality-of-life-in-children-and-adolescents-with-%C3%AE-thalassemia-major-on-different-iron-chelators-in-basra-iraq
#13
Hadeel A-I Abdul-Zahra, Mea'ad K Hassan, Bahaa A A H Ahmed
Few studies have investigated the quality of life of children with thalassemia in the Middle East or Mediterranean region, especially Iraq. Therefore, this study was performed to assess the health-related quality of life (HRQoL) of patients with β-thalassemia major compared with healthy children and adolescents in the same age group and to evaluate the effects of different iron chelators on HRQoL measurements. A case-control study was performed on patients with β-thalassemia major registered at the Center for Hereditary Blood Diseases in Basra from February 2012 through July 2013...
October 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27602957/the-iron-chelator-deferasirox-induces-apoptosis-by-targeting-oncogenic-pyk2-%C3%AE-catenin-signaling-in-human-multiple-myeloma
#14
Yusuke Kamihara, Kohichi Takada, Tsutomu Sato, Yutaka Kawano, Kazuyuki Murase, Yohei Arihara, Shohei Kikuchi, Naotaka Hayasaka, Makoto Usami, Satoshi Iyama, Koji Miyanishi, Yasushi Sato, Masayoshi Kobune, Junji Kato
Deregulated iron metabolism underlies the pathogenesis of many human cancers. Recently, low expression of ferroportin, which is the only identified non-heme iron exporter, has been associated with significantly reduced overall survival in multiple myeloma (MM); however, the altered iron metabolism in MM biology remains unclear. In this study we demonstrated, by live cell imaging, that MM cells have increased intracellular iron levels as compared with normal cells. In experiments to test the effect of iron chelation on the growth of MM cells, we found that deferasirox (DFX), an oral iron chelator used to treat iron overload in clinical practice, inhibits MM cell growth both in vivo and in vitro...
September 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27595699/correlation-between-liver-iron-concentration-determined-by-magnetic-resonance-imaging-and-serum-ferritin-in-adolescents-with-thalassaemia-disease
#15
Ampaiwan Chuansumrit, Jiraporn Laothamathat, Nongnuch Sirachainan, Witaya Sungkarat, Pakawan Wongwerawattanakoon, Patrapop Kumkrua
BACKGROUND: MRI imaging is an alternative to serum ferritin for assessing iron overload in patients with thalassaemia disease. AIMS: To correlate liver iron concentration (LIC) determined by MRI and clinical and biochemical parameters. METHODS: An MRI study using cardiovascular magnetic resonance (CMR) tools to determine cardiac and liver iron was undertaken in adolescents with thalassaemia disease. RESULTS: Eighty-nine patients (48 males) with thalassaemia disease were enrolled...
August 2016: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/27589737/the-iron-chelator-dp44mt-effectively-inhibits-human-oral-squamous-cell-carcinoma-cell-growth-in-vitro-and-in-vivo
#16
Jehn-Chuan Lee, Kun-Chun Chiang, Tsui-Hsia Feng, Yu-Jen Chen, Sung-Ting Chuang, Ke-Hung Tsui, Li-Chuan Chung, Horng-Heng Juang
Oral squamous cell carcinoma (OSCC) is a common malignancy with a growing worldwide incidence and prevalence. The N-myc downstream regulated gene (NDRG) family of NDRG1, 2, 3, and mammary serine protease inhibitor (Maspin) gene are well-known modulators in the neoplasia process. Current research has considered iron chelators as new anti-cancer agents; however, the anticancer activities of iron chelators and their target genes in OSCC have not been well investigated. We showed that iron chelators (Dp44mT, desferrioxamine (DFO), and deferasirox) all significantly inhibit SAS cell growth...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27582255/deferasirox-a-novel-oral-iron-chelator-shows-antiproliferative-activity-against-pancreatic-cancer-in-vitro-and-in-vivo
#17
Hirofumi Harima, Seiji Kaino, Taro Takami, Shuhei Shinoda, Toshihiko Matsumoto, Koichi Fujisawa, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida
BACKGROUND: Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for cancer. Deferasirox (DFX), a novel oral iron chelator, has been successful in clinical trials in iron-overload patients and has been expected to become an anticancer agent. However, no studies have investigated the effects of DFX on pancreatic cancer. This study aimed to elucidate the effects of DFX against pancreatic cancer...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27576370/one-year-results-from-a-prospective-randomized-trial-comparing-phlebotomy-with-deferasirox-for-the-treatment-of-iron-overload-in-pediatric-patients-with-thalassemia-major-following-curative-stem-cell-transplantation
#18
Adlette Inati, Mario Kahale, Nada Sbeiti, Maria Domenica Cappellini, Ali T Taher, Suzanne Koussa, Therese A Nasr, Khaled M Musallam, Hussein A Abbas, John B Porter
BACKGROUND: Iron overload is well documented in patients with β-thalassemia major, and patients who have undergone hematopoietic stem cell transplantation (HSCT) remain at risk as a result of pre- and immediate post-HSCT transfusions. PROCEDURE: This is a prospective, randomized, 1-year clinical trial that compares the efficacy and safety of the once-daily oral iron chelator deferasirox versus phlebotomy for the treatment of iron overload in children with β-thalassemia major following HSCT...
August 31, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27548339/evaluation-of-proteinuria-in-%C3%AE-thalassemia-major-patients-with-and-without-diabetes-mellitus-taking-deferasirox
#19
Mehran Karimi, Abbas Avazpour, Sezaneh Haghpanah, Foroogh Toosi, Arash Badie
BACKGROUND: β-thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the deferasirox is proteinuria. OBJECTIVES: This study aimed to investigate the safety of deferasirox on kidney function in diabetic and nondiabetic β-thalassemia major patients. MATERIALS AND METHODS: In this cross-sectional study, 34 diabetic and 36 nondiabetic patients who take deferasirox (Exjade) 20 to 40 mg/kg/d were studied...
August 19, 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27548334/longitudinal-mri-and-ferritin-monitoring-of-iron-overload-in-chronically-transfused-and-chelated-children-with-sickle-cell-anemia-and-thalassemia-major
#20
Mélodie Aubart, Phalla Ou, Caroline Elie, Carla Canniffe, Shelby Kutty, Vincent Delos, Christine Graffigne, Mariane de Montalembert, Valentine Brousse
Iron overload is an ineluctable complication in chronically transfused children warranting accurate assessment to avoid related morbidity. We investigated longitudinally the relationships between ferritin levels and hepatic and cardiac T2* magnetic resonance imaging (MRI) in a cohort of chronically transfused children receiving chelation therapy. Thirty children with sickle cell anemia (SCA) and 7 with thalassemia major (TM) chelated similarly by deferasirox were analyzed. Sex ratio, age, median duration of transfusion programs (5 y; range, 2 to 14 y), median transfusion iron intake 0...
October 2016: Journal of Pediatric Hematology/oncology
keyword
keyword
19933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"